Expression of EGFR and Bcl-2 in breast cancer and their relationship with clinicopathological features
LIU Guangxu1,REN Shengnan2,FANG Xuedong2, HE Yan1
1.Department of Epidemiology and Biostatistics, School of Public Health, Capital Medical University, Beijing 100069,China; 2.Department of General Surgery, China-Japan Union Hospital of Jilin University, Changchun 130021, China
Abstract：Objective To study the expression of epidermal growth factor receptor (EGFR) and B-cell lymphoma-2 (Bcl-2) in breast cancer subtype and their relationship with clinicopathological features and the expression of ER,PR and HER-2. Methods Immunohistochemistry was performed to detect the expression of EGFR and Bcl-2 in 539 patients with breast cancer and its correlation with clinicopathological parameters was analyzed. Results The expression rate of EGFR in three negative breast cancer group (χ2=9.78,P=0.008) and Bcl-2 in luminal breast cancer group (χ2=114.11, P<0.0001) were 44.4% and 71.7%, which were the highest in all groups. The expression of EGFR showed a statistically significant difference in histological grade (χ2=11.38,P=0.003), and the expression of Bcl-2 showed a statistically significant difference in histological grade (χ2=6.92, P=0.041) and pathological type (χ2=5.39,P=0.022). No significant difference was found between the expression of both and other clinicopathological features. The expression of PR and Bcl-2 was positively correlated with the expression of Bcl-2, and their correlation coefficients were 0.712(P<0.01) and 0.599(P<0.01), respectively, which was the same with the expression between PR and Bcl-2 (r=0.599,P<0.01). However, there was a negative correlation between ER,PR and HER-2, Bcl-2 respectively, and their correlation coefficient were -0.366,-0.133,-0.453,-0.392 successively. In addition, no correlation was found between EGFR and HER-2, Bcl-2 (P>0.05). Conclusions The expression of EGFR and Bcl-2 is different in breast cancer subtypes. Joint detection of the expression of EGFR and Bcl-2 could be used as index of breast cancer occurrence, development, and help to guide clinical treatment and prognosis of strategy.
刘光旭, 任圣楠, 房学东, 何燕. 乳腺癌表皮生长因子受体与Bcl-2的表达及其临床意义[J]. 武警医学, 2015, 26(4): 383-386.
LIU Guangxu,REN Shengnan,FANG Xuedong, HE Yan. Expression of EGFR and Bcl-2 in breast cancer and their relationship with clinicopathological features. Med. J. Chin. Peop. Armed Poli. Forc., 2015, 26(4): 383-386.
Balslev I, Axelsson C K, Zedeler K, et al. The Nottingham Prognostic Index applied to 9,149 patients from the studies of the Danish Breast Cancer Cooperative Group (DBCG) [J]. Breast Cancer Res Treat, 1994, 32(3):281-290.
[2]
Burness M L, Grushko T A, Olopade O I.Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a marker[J]. Cancer J, 2010, 16(1):23-32.
[3]
Park S, Koo J S, Kim M S,et al. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry [J]. Breast, 2012, 21(1):50-57.
[4]
Gehrig P A, Van L L, Olatidoye B. Estrogen receptor status, determined by immunohistochemistry, as a predictor of the recurrence of stage I endometrial carcinoma [J]. Cancer, 1999, 86(10):2083-2089.
Cheang, M C, Chia S K, Voduc D,et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer [J]. J Natl Cancer Inst, 2009, 101(10):736-750.
Nicholson R I. EGFR and cancer prognosis [J]. Eur J Cancer, 2001, 37 (4):9-15.
[12]
Nielsen T O, Hsu F D, Jensen K,et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma [J]. Clin Cancer Research, 2004, 10(16):5367-5374.
[13]
Kim M J, Ro J Y, Ahn S H,et al. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes [J]. Human pathology, 2006, 37(9):1217-1226.
[14]
Zaha D C, Lazar E, Lazureanu C, et al. Clinicopathologic features and five years survival analysis in molecular subtypes of breast cancer [J]. Rom J Morphol Embryol, 2010, 51(1):85-89.
[15]
Hellemans P, van Dam P A, Weyler J,et al. Prognostic value of bcl-2 expression in invasive breast cancer [J]. Br J Cancer, 1995, 72(2):354-360.
Gee J M, Ellis I O, Robertson J F,et al. Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy [J]. Int J Cancer, 1994, 59(5):619-628.
[19]
Rolland P, Spendlove I, Madjd Z,et al. The p53 positive Bcl-2 negative phenotype is an independent marker of prognosis in breast cancer [J]. Int J Cancer, 2007, 120(6):1311-1317.
[20]
dos Santos LG, Lopes-Costa P V, dos Santos A R,et al. Bcl-2 oncogene expression in estrogen receptor-positive and negative breast carcinoma [J]. Eur J Gynaecol Oncol, 2008, 29(5):459-461.
McCawley L J, O’Brien P, Hudson L G. Overexpression of the epidermal growth factor receptor contributes to enhanced ligand-mediated motility in keratinocyte cell lines[J]. Endocrinology. 1997, 138(1):121-127.
[23]
Sibilia M, Fleischmann A, Behrens A,et al. The EGF receptor provides an essential survival signal for SOS-dependent skin tumor development [J]. Cell,2000,102(2):211-220.
2015, Vol. 26 
